Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 7, 2011, Pages 1653-1654

  Luque, Sonia ^a   Grau, Santiago ^a   Valle, Marta ^a   Colino, Clara Isabel ^b   Ferrer, Antoni ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Drug administration schedule; Fluoroquinolones; Morbid obesity; Pharmacokinetics pharmacodynamics; Therapeutic drug monitoring

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GLUCOSE; LEVOFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; BODY WEIGHT; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ECG ABNORMALITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCAPNIA; LETTER; LOWER RESPIRATORY TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; MORBID OBESITY; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; RESPIRATORY FAILURE; SIDE EFFECT; SLEEP APNEA SYNDROME; SPUTUM CULTURE; STEADY STATE; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

EID: 79958856036     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr146     Document Type: Letter

References (7)

1. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
2. Hollenstein UM, Brunner M, Schmid R et al. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord 2001; 25: 354-8.
3. Allard S, Kinzig M, Boivin G et al. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Therap 1993; 54: 368-73.
4. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
5. Chow AT, Fowler C, Williams RR et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001; 45: 2122-5.
6. Caldwell JB. Intravenous ciprofloxacin dosing in a morbidly obese patient. Ann Pharmacother 1994; 28: 806.
7. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001; 14: 165-72.